Últimas noticias sobre Biora Therapeutics (NASDAQ:BIOR) Bolsa

Biora Therapeutics

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.

Biora Therapeutics Inc

BioRegenx Inc

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

Biorem Inc

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Biora Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bior-stock-quote/"><strong>BIOR</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Biora Therapeutics reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -45 cents.</li><li>The company reported revenue of $542,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/bior-stock-earnings-biora-therapeutics-for-q1-of-2024/">BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024

Biora Therapeutics (BIOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis ...

Biora Therapeutics: A Strong Buy on Robust Q1 Performance and Promising Drug Delivery Platforms

An announcement from Biora Therapeutics (BIOR) is now available. Biora Therapeutics, Inc. has announced encouraging preliminary results from its BT...

Biora Therapeutics Reports Promising BT-600 Trial Results

Biora Therapeutics (BIOR) has shared an announcement. Biora Therapeutics recently revealed promising supplemental data from its Phase 1 trial of BT...

Biora Therapeutics Advances Ulcerative Colitis Treatment with BT-600 Trial Success

Biora Therapeutics GAAP EPS of -$0.04 beats by $0.41, revenue of $0.32M

Biora Therapeutics (BIOR) just unveiled an update. Biora Therapeutics, Inc. has initiated a strategic financial maneuver involving a debt exchange ...

Biora Therapeutics Restructures Debt and Issues New Securities

Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Biora Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bior-stock-quote/"><strong>BIOR</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Biora Therapeutics reported earnings per share of -4 cents. This was above the analyst estimate for EPS of -45 cents.</li><li>The company reported revenue of $318,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/bior-stock-earnings-biora-therapeutics-for-q2-of-2024/">BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics (BIOR – Research Report), with a pr...

Comments

Biora Therapeutics

Noticias

Últimas noticias sobre Biora Therapeutics (NASDAQ:BIOR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL